Medical Prognosis Institute A/S - Interim Report First Half 2014

August 12, 2014 11:43 ET | Source: Allarity Therapeutics, Inc.

Hoersholm; April 12th 2014 - Medical Prognosis Institute A/S (MPI) announces the Company's Interim Report First Half 2014.

Interim Report First Half 2014

The Board of Directors for Medical Prognosis Institute A/S has today discussed and approved the Interim Report First Half 2014.

This announcement contains the full Interim Report First Half 2014.

For further information please contact

Peter Buhl Jensen, CEO

e-mail: pbj@medical-prognosis.com

Cell Phone: +45 21 60 89 22

Certified Advisor: Carsten Yde Hemme, PricewaterhouseCoopers, Strandvejen 44, 2900 Hellerup, Denmark

Attachments

MPI - Interim Report First Half 2014

MPI - Interim Report First Half 2014...

MPI - Interim First Half 2014

MPI - Interim First Half 2014...

Recommended Reading

September 30, 2026 09:00 ET | Source: Allarity Therapeutics, Inc.

Allarity Provides Update on Key Recent Advances Solidifying Drug Response Predictor® to Drive Stenoparib’s Clinical Development

- Recently awarded patents have solidified Allarity’s strategy to leverage DRP to ensure the commercial exclusivity of stenoparib TARPON SPRINGS, Fla., September 30, 2026 – Allarity Therapeutics,...
Read More
September 28, 2026 08:00 ET | Source: Allarity Therapeutics, Inc.

Allarity Therapeutics Expands Laboratory Capabilities to Include Proteomics and Cell Line Research

- Expanded laboratory capabilities support deeper mechanism-of-action research for stenoparib - New proteomics and cell line capabilities will broaden Allarity’s research capabilities to...
Read More